All News Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

Delayed Nasdaq Other stock markets 02:00:00 18/05/2024 am IST			5-day change	1st Jan Change
2.85 ^USD	-0.00%		-9.52%	-14.93%

07/05	Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
05/03	Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cyclerion Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03	CI
Cyclerion Appoints Regina Graul, Ph.D., as President	04/12	AQ
Cyclerion Therapeutics, Inc. Appoints Regina Graul as President	04/12	CI
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator	01/12	AQ
Cyclerion Therapeutics, Inc. Announces Board of Directors Appointments	01/12	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Ole Isacson as Director	24/11	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	14/11	CI
Cyclerion Therapeutics, Inc. Announces Anjeza Gjino Resigns as Chief Financial Officer	24/23/24	CI
Cyclerion Therapeutics, Inc. - Tisento Launches with $81 Million from Top-Tier Investor Syndicate and Promising Cyclerion Assets	01/23/01	AQ
Cyclerion Therapeutics Acquires 10% Stake in Tisento Therapeutics in Asset Purchase Deal	31/23/31	MT
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets	31/23/31	AQ
Tisento Therapeutics, Inc. announced that it has received $81 million in funding from Cyclerion Therapeutics, Inc., Invus, Polaris, and other investors	31/23/31	CI
Cyclerion Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29/23/29	CI
Cyclerion Therapeutics, Inc. Announces Resignation of Cheryl Gault as Chief Operating Officer	28/23/28	CI
CYCLERION THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K)	02/23/02	AQ
Cyclerion Regains Compliance with Nasdaq Minimum Bid Price Requirement	02/23/02	AQ
Cyclerion Therapeutics : Private Placement - Form 8-K	26/23/26	PU
CYCLERION THERAPEUTICS, INC. : Unregistered Sale of Equity Securities, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)	26/23/26	AQ
Cyclerion Therapeutics, Inc. announced that it has received $5.000001 million in funding	25/23/25	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Cyclerion Therapeutics, Inc.

Equities

CYCN

US23255M2044

All News

Filters